| Similar Articles |
|---|
 |
Bio-IT World
February 18, 2004 |
On the Up and Up Market values for biotec companies increase as they deal and deliver in the fourth quarter   |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
Bio-IT World
November 14, 2003
Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. |
Bio-IT World
May 19, 2004
Branca, Hoffer & Nambiar |
Keeping an Even Keel Bland first quarter was punctuated by HGS mini-drama: Biotech guru Steven Burrill hailed the first quarter of 2004 as biotech's best funding quarter in the industry's 30-year history. But it was also a strange one. |
Bio-IT World
November 19, 2004
Hoffer & Nambiar |
Mirus Index Heads South Overall, companies in the Mirus Index declined in the third quarter of 2004. |
Bio-IT World
May 9, 2003
Malorye Branca |
Discovering the Joy of Cannibalism Persistent financial pressures feed continuing consolidation among struggling genomics companies |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
Pharmaceutical Executive
July 1, 2006
Deborah Dunsire |
Thoughtleader: Targeted Expansion Millennium Pharmaceuticals' CEO discusses what's ahead for the company, its success through partnerships, and why it believes it can lead the pack in targeted therapeutics. |
The Motley Fool
December 27, 2007
Brian Lawler |
A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma. |
The Motley Fool
January 8, 2007
Brian Lawler |
Millennium Looks Ahead Shares of the biopharmaceutical company ended the year more than 10% higher, despite the presence of increased competition for its cancer treatment Velcade and all sorts of attempted merger and acquisition activity within the company. The pharmaceutical foresees a mixed 2007. |
The Motley Fool
July 22, 2004
Charly Travers |
A Millennium Pharmaceuticals Mix Sales for one drug are encouraging, while sales for another one are declining. |
The Motley Fool
October 30, 2006
Brian Lawler |
Millennium Is So Last Century The drug company released its third-quarter results last week, and there is not much particularly exciting therein. None of its drug candidates is in late-stage testing and all are years away from approval, except for follow-on indications for Velcade. Investors, take note. |
BusinessWeek
July 21, 2003
Gene G. Marcial |
A Rosier Millennium? Jump into Millennium Pharmaceuticals stock. That's the word from some Millennium trackers who think its recent fall -- from 17.20 in mid-June to 14 on July 1 -- was unwarranted. It is now at 15. |
Bio-IT World
May 7, 2002
Malorye Branca |
In Silico Survivors Facing desperate times, bioinformatics companies revamp, refocus, or perish. |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
October 9, 2006
Brian Lawler |
Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note. |
The Motley Fool
January 31, 2008
Brian Lawler |
Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug. |
The Motley Fool
April 30, 2007
Brian Lawler |
The Future Millennium Isn't So Exciting Biotech drugmaker Millennium Pharmaceuticals released its quarterly financial results. Investors, take note. |
The Motley Fool
December 15, 2003
W.D. Crotty |
Millennium Celebration Millennium took just four and a half years to push Velcade from first human dose to FDA approval, and the company has financial muscle most biotechnology companies only dream about. |
The Motley Fool
November 6, 2007
Brian Lawler |
It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
Bio-IT World
September 9, 2002
Malorye Branca |
In Like a LION ... The Once and Future King? LION Biosciences CEO Friedrich von Bohlen talks about his undaunted support for his vision for the company. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
The Motley Fool
July 27, 2007
Brian Lawler |
Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
July 10, 2009
Brian Orelli |
Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders. |
The Motley Fool
March 26, 2004
Charly Travers |
Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs. |
Bio-IT World
September 11, 2003
Richard D. Gill |
The Challenge for in silico Drug Companies Is this the end of the in silico drug discovery and development market? |
Bio-IT World
February 10, 2003
Malorye Branca |
The Art of the Deal Vertex Pharmaceuticals CEO Joshua Boger speaks about deal making and his company's success. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Pharmaceutical Executive
February 1, 2014
William Looney |
Takeda' Oncology Taskmaster Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge; and a lead position in the hotly contested search to make cancer a treatable disease. |
The Motley Fool
November 4, 2005
Stephen D. Simpson |
A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals... |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Bio-IT World
November 2005
Kevin Davies |
A Win-Win Situation The inaugural Bridging Discovery and IT conference explored critical issues facing discovery, clinical, and IT teams struggling to communicate and collaborate in biopharma organizations. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
May 18, 2007
Mike Havrilla |
Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note. |
